INS and cancer: GPCR agonists support these conclusions by indirectly transactivating insulin receptors via Neu-1 mediated desialylation of IRβ subunits without insulin, highlighting that the IR plays a critical role in maintaining the vitality of cancer cells and creates a therapeutic target for the treatment of these diseases [224].